CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- S-3ASR Offering Registration Statement
- 8-K Event Material agreement
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Legal Officer sold 20,416 shares at an average $23.45 ($478,845)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Legal Officer sold 45,000 shares at an average $24.08 ($1,083,718)
- 4 Open-market sale Chief Financial Officer sold 87,339 shares at an average $26.45 ($2,310,106)
- 4 Open-market sale President and CEO sold 30,000 shares at $26.84 ($805,239)
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Shares withheld for taxes Chief Medical Officer gave up 7,940 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Legal Officer gave up 6,840 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 10,177 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 47,774 shares (to pay taxes)
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 20 of 44 · 872 filings